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Abstract
Introduction: Management of inflammatory bowel diseases 
(IBDs) – both Crohn’s disease (CD) and ulcerative colitis (UC) 
– during pregnancy can be challenging since most monitor-
ing tools available in nonpregnant patients are contraindi-
cated. Objectives: The aim of the study was to test whether 
fecal inflammatory markers – specifically fecal lactoferrin – 
physiologically change during normal pregnancy as a pre-
requisite to use them to monitor IBD activity during preg-
nancy. Methods: Fecal lactoferrin was tested in healthy 
pregnant and nonpregnant women from the same geo-
graphic area and age range (18–40 years) – all negative for 
clinical gastrointestinal tract inflammation. A retrospective 
review of fecal lactoferrin levels contrasted with the Simple 
Endoscopic Score for CD, and the Disease Activity Index for 
UC was also performed in women with active IBDs within the 
same age range and geographical area. Results: In 30 non-
pregnant subjects, fecal lactoferrin levels were 0.87 ± 1.08 
μg/g. In 49 pregnant subjects, levels were 0.59 ± 0.83, 0.87 ± 
1.13, and 0.85 ± 1.06 μg/g during the first, second, and third 
trimester, respectively (p = 0.64), with average levels for the 
3 trimesters of 0.81 ± 1.04 μg/g (p = 0.61 compared to non-
pregnant subjects). Sequential fecal lactoferrin levels (n = 26) 
did not differ from one trimester to the other in the individu-
al subjects (p = 0.80). In 45 female IBD patients (27 with CD 
and 18 with UC), fecal lactoferrin levels were correlated with 
disease activity as defined by the endoscopic scores: 218, 
688, and 1,175 μg/g for CD and 931, 2,088, and 2,509 μg/g for 
UC, respectively, for mild, moderate, and severe activity. Con-
clusions: Fecal lactoferrin levels during normal pregnancy 
are superimposable to those of nonpregnant women and 
significantly below levels in women of the same childbearing 
age with active IBDs. Additional published data – reviewed in 
this atricle – and our own indicate that fecal lactoferrin and 
other markers can be potentially used to monitor disease ac-
tivity in pregnant IBD patients. © 2020 The Author(s).
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Inflammatory bowel diseases (IBDs) – Crohn’s disease 
(CD) and ulcerative colitis (UC) – are most often diag-
nosed in the second through fourth decades of life which, 
for female patients, coincide with their childbearing years 
[1, 2] when changes due to pregnancy may affect disease 
activity. Adverse outcomes such as gestational diabetes, 
preterm delivery, cesarean delivery, small for gestational 
age, stillbirth, spontaneous abortion, and congenital 
anomalies occur at an increased rate among women with 
active IBD [3–5]. Perhaps, due to the uncertainty of the 
disease impact on pregnancy, the rate of voluntary child-
lessness among women with IBDs is higher than that of 
the general population [6]. The rate of flares during preg-
nancy is related to disease activity at the time of concep-
tion. Increased disease activity at the time of conception 
is associated with an increased risk of flares later during 
the pregnancy [7]. Disease remission and flare prevention 
during pregnancy have been shown to decrease pregnan-
cy-related complications [8]. Therefore, disease monitor-
ing is crucial in this population. Endoscopy, the gold stan-
dard in IBD monitoring, carries significant risks during 
pregnancy. Both costly and invasive, endoscopy is usu-
ally reserved for emergency use during the second trimes-
ter [9]. It has been found to negatively impact the fetus 
and increase the risk for low gestational weight and pre-
term birth [10]. Imaging generally plays an important 
role in monitoring IBDs; however, in pregnant women, 
imaging might also be associated with risks. Computed 
tomography (CT) scans might pose risks of teratogenic-
ity, and iodine-based contrast agents may negatively im-
pact fetal thyroid function [9, 11]. Magnetic resonance 
imaging (MRI) without contrast is considered safe during 
pregnancy – however, due to its scarce availability and 
cost, it is not always a viable monitoring technique for 
pregnant women. In addition, it has limited applications 
for colonic disease [12]. Small bowel ultrasound can de-
tect inflammation, and it is safe during pregnancy, but its 
accuracy might not be enough to guide management, un-
less performed by expert operators [12]. Serum biomark-
ers used to assess inflammation and disease activity such 
as C-reactive protein (CRP), albumin, and hemoglobin 
have been found to be altered by normal pregnancy phys-
iology and, therefore, may not correlate with disease ac-
tivity [13]. Hence, the lack of simple, noninvasive tools to 
monitor the disease, detect a possible flare, and adjust 
therapy during pregnancy is a serious issue faced by preg-
nant women with IBDs.
Fecal biomarkers have emerged as an important tool 
in managing these diseases. They allow for noninvasive 
accurate monitoring of IBD activity without the risks as-
sociated with other methods. Among the others, fecal lac-
toferrin has been shown to be sensitive and specific for 
detecting active disease in IBD patients [14–16].
Lactoferrin, an 80-kDa iron-binding glycoprotein, is 
expressed by activated neutrophils. Lactoferrin concen-
tration in feces is the result of neutrophil translocation to 
the lining of the gastrointestinal tract during intestinal 
inflammation [17]. Therefore, the presence of lactoferrin 
in feces is indicative of an immune response and an indi-
cator of inflammation. Scarce data currently exist for nor-
mal fecal lactoferrin levels in healthy pregnant women. In 
principle, like serum biomarkers, lactoferrin could be al-
tered by normal pregnancy physiology and become inac-
curate to monitor IBDs. Therefore, the aim of this study 
was to determine baseline levels of lactoferrin during 
pregnancy in healthy women.
Materials and Methods
In this study, 3 distinct subject populations were studied. 
Group 1 was composed of healthy nonpregnant women of child-
bearing age from southwest Virginia, USA, and served as controls. 
The stool samples were collected during an open sample drive per-
formed by TechLab (Blacksburg, VA, USA). Fecal samples were 
collected at home by the subjects using standard methods. Indi-
viduals in this group (1) were between the ages of 18 and 40 years; 
(2) had no history of IBDs or other known upper or lower gastro-
intestinal tract diseases (including but not limited to celiac disease, 
irritable bowel syndrome, diverticulitis, and Clostridium difficile 
colitis); and (3) were not using NSAIDs or any other potentially 
toxic medications for the gastrointestinal tract. Subjects who had 
been diagnosed with an immune-mediated inflammatory 
disease(s) that could potentially be associated with inflammation 
of the intestine were also excluded.
Group 2 was composed of healthy pregnant women from the 
same geographical area of the controls who provided fecal samples 
throughout their pregnancy during each of the 3 trimesters to be 
tested for fecal lactoferrin. A maximum of 3 samples, one from 
each trimester, was collected from each subject. These fecal sam-
ples were collected from the patient population of Carilion Clinic’s 
Obstetrics & Gynecology Department and local private practices 
outside Carilion Medical Center. These subjects at the time of sam-
ple collection had a normal uncomplicated pregnancy. Eligibility 
criteria for group 2 were identical to those of group 1 with the ad-
dition of a positive pregnancy status confirmed by a physician. 
Subjects who were seeing physicians outside of the Carilion Clinic 
network were asked to provide their medical history from their 
physician’s office. For the others, the medical history was available 
in their electronic medical records. Fecal samples were collected at 
home by the subjects using standard methods and brought with 
them during their scheduled appointments with the obstetrician 




or at a set time and location. Participating individuals received re-
imbursement for their time. For each subject, the demographics, 
medical history (including social history), and clinical parameters 
were collected during the study. Laboratory studies in addition to 
fecal lactoferrin included standard routine blood tests. All fecal 
samples were kept at −20°C until the time of transportation to the 
lab for analysis. Tests were performed at TechLab, Blacksburg, VA. 
Fecal lactoferrin was measured by enzyme immunoassay, and re-
sults are reported as μg/g feces. Group 3 was composed of non-
pregnant women with active IBDs (UC or CD). This group was 
used as a reference group to verify correlation of fecal lactoferrin 
with disease activity in this population of childbearing age (18–40 
years) all coming from the same geographical area of the subjects 
of group 1 and 2. The subjects were identified utilizing a retrospec-
tive chart review of previously established IBD patients with Car-
ilion Clinic Medical Center. Inclusion criteria for this group in-
cluded (1) clinically active IBDs with recent endoscopy and re-
ported Simple Endoscopic Score for CD (SES-CD) or the 
endoscopic component of the Mayo Clinical Score (Disease Activ-
ity Index [DAI]) for UC [18], (2) fecal lactoferrin tested within 30 
days of endoscopy, and (3) verified nonpregnant status. The SES-
CD is defined as follows: remission (score 0–2), mild inflammation 
(score 3–6), moderate inflammation (score 7–15), and severe in-
flammation (score ≥16). The endoscopic component of the DAI is 
defined as follows: normal or inactive disease (score 0), mild dis-
ease (score 1), moderate disease (score 2), and severe disease (score 
3).
The study protocol was approved by the Carilion Clinic Insti-
tutional Review Board. Subjects who agreed to participate signed 
the informed consent.
Results
Group 1 – nonpregnant healthy women within 18–40 
years of age – included 30 subjects tested for fecal lacto-
ferrin levels. Levels ranged from 0.01 to 3.81 μg/g with a 
mean level ± SD of 0.87 ± 1.08 μg/g.
Group 2 – healthy pregnant women – included 49 sub-
jects within 18–40 years of age. Their clinical features are 
shown in Table 1. A minority of these subjects were to-
bacco or marijuana users. Mean levels were obtained by 
pooling the results of all enrolled study subjects per tri-
mester. During the first trimester, mean fecal lactoferrin 
levels were 0.59 ± 0.83 μg/g; during the second trimester, 
the mean lactoferrin levels were 0.87 ± 1.13 μg/g; and dur-
ing the third trimester, the levels were 0.85 ± 1.06 μg/g. 
The mean fecal lactoferrin value for pregnant women 
over all 3 trimesters (0.81 ± 1.04 μg/g) was not different 
from the mean levels in healthy women of group 1 (p = 
0.61). There was also no difference between the mean fe-
cal lactoferrin values between the 3 trimesters (ANOVA 
test: p = 0.64). Sequential individual samples were avail-
able for 26 subjects. Their fecal lactoferrin values did not 
differ from 1 trimester to the other in the individual sub-
jects (ANOVA p = 0.80). Two of the study subjects in this 
group had elevated fecal lactoferrin levels. One of them 
had a value of 86 μg/g during the third trimester with nor-
mal levels during the first and second trimesters (0.39 and 
0.78 μg/g, respectively). This subject’s pregnancy was 
complicated by excessive maternal weight gain (with a 
BMI of 54), maternal depression, gestational hyperten-
Table 1. Healthy pregnant subjects characteristics (n = 49)
Demographics
Age in years, range 18–40
Ethnicity
White, non-Hispanic, n (%) 31 (63)
Black, n (%) 14 (29)
Hispanic, n (%) 3 (6)
Biracial, n (%) 1 (2)
Social history
Tobacco use: current, former, and 
never, n (%)
16 (33), 9 (18), and 
24 (49)
Marijuana use: current, former, and 
never, n (%)
4 (8), 5 (10), and 
40 (82)
Table 2. IBD patients characteristics (n = 45)
Demographics
Age in years, range 18–40
Ethnicity
White, non-Hispanic, n (%) 40 (89)
Black, n (%) 5 (11)
Social history
Tobacco use: current, former, and 
never, n (%)




CD, n (%) 27 (60)
UC, n (%) 18 (40)
Disease duration in years (SD) 3.7 (5.3)
SES-CD
Mild, n (%) 8 (30)
Moderate, n (%) 8 (30)
Severe, n (%) 11 (40)
DAI (UC)
Mild, n (%) 6 (33)
Moderate, n (%) 5 (28)
Severe, n (%) 7 (39)
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, 






sion, and tobacco, marijuana, and alcohol abuse. Addi-
tionally, this subject had an increased WBC count (17.7 
K/μL) during the third trimester. She experienced arrest 
of dilation during labor and delivered the fetus by cesar-
ean section. At time of delivery, the infant appeared 
healthy. Due to the presence of confounding factors and 
possible risks for gastrointestinal tract inflammation, she 
was excluded from the analyses. The second patient had 
elevated fecal lactoferrin levels during the first trimester 
(28 μg/g). The subject did not collect samples during the 
second or third trimester having started NSAIDs. She had 
a complicated pregnancy exacerbated by uncontrolled 
type 2 diabetes, hyperlipidemia, multiple urinary tract in-
fections, and gestational hypertension. She also had a his-
tory of complicated pregnancies with fetal anomalies, 
preterm deliveries, and stillbirths. At the time of delivery, 
no abnormalities or medical issues for the mother or in-
fant were recorded. Again, due to the presence of con-
founding factors and a complicated pregnancy, the data 
relative to this patient were excluded from the analyses.
Group 3 – nonpregnant women with active IBDs – in-
cluded 45 subjects within 18–40 years of age of whom 27 
had CD and 18 UC (Table 2). The distribution of SES-CD 
and DAI scores for mild, moderate, and severe disease 
was similar in this group. Figure 1 shows the lactoferrin 
values – performed within 30 days of endoscopy – as they 
relate to the endoscopy scores in this group of female pa-
tients. For CD patients, the mean lactoferrin levels for 
mild, moderate, and severe disease as defined by the SES-
CD score were 217, 688, and 1,175 μg/g, respectively. For 
UC patients, mean lactoferrin levels for mild, moderate, 
and severe disease as defined by the DAI score were 931, 
2,088, and 2,509 μg/g, respectively.
Discussion
Pregnancy poses challenges for women with IBDs. 
Many feel uncertain about treatment during pregnancy 
– mainly because of potential side effects of the medica-
tions on their unborn child [6]. Indeed, many of the med-
ications used to treat IBDs have been found in the breast 
milk of nursing mothers [19, 20]. Fears of heritability, risk 
of congenital abnormalities, and medication teratogenic-
ity all effect the decision to bear children for women with 
IBDs.
Monitoring disease activity and diagnosing a flare pos-
es special problems during pregnancy since typical tools 
such as endoscopy and imaging are contraindicated ex-
cept in emergency circumstances. Endoscopy might be 
associated with an increased risk of complications such as 
low gestational weight and preterm birth [10]. Imaging 
– including CT, MRI, and ultrasound – also has limita-
tions and shortcomings. CT increases the risk of terato-
genicity and is contraindicated during pregnancy. Non-
contrast MRI is considered safe, but cost and availability 
are a major limiting factor in addition to its limited accu-
racy for colonic disease [12]. Intestinal ultrasound is safe 
even during pregnancy; however, it is an imaging test that 
requires special expertise and it is not widely available 
[12].
Fecal biomarkers, such as lactoferrin, are accurate in-
dicators of inflammation as well as being noninvasive and 
inexpensive [21–25]. Hence, they could be ideally suited 
to monitor IBD activity during pregnancy. However, 
pregnancy is known to be associated with a number of 
physiological changes such as systemic hormonal shifts 
and immunological changes [26–28] which might be 
partly responsible for several alterations in hematological 
parameters, including leukocyte number [29]. Hence, it 
is important to verify that inflammatory markers do not 
change during normal pregnancy as a prerequisite to 
their use to monitor disease activity in pregnant IBD pa-
tients. In this study, we focused on fecal lactoferrin which 
appears to be an accurate predictor of IBD flares in non-
pregnant patients [15, 16, 24]. We compared fecal lacto-
ferrin values during normal pregnancy to those of healthy 
nonpregnant women and to those of women with active 
























Fig. 1. Fecal lactoferrin values in relation to endoscopy scores 
(SES-CD for CD patients and DAI for UC patients) in a group of 
female IBD patients within the same age range (18–40 years) of the 
pregnant subjects. Values were correlated with disease activity. 
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcer-
ative colitis; SES-CD, Simple Endoscopic Score for CD; DAI, Dis-
ease Activity Index.




Our results show that fecal lactoferrin levels do not 
change during any of the 3 trimesters of pregnancy com-
pared to those of nonpregnant controls. We did observe 
elevated biomarker levels in 2 women with a significant 
medical history and complicated pregnancies. Due to the 
lack of additional information related to the gastrointesti-
nal tract in these 2 subjects, the mechanism(s) at the basis 
of their increased fecal lactoferrin levels was unclear. We 
cannot exclude intestinal ischemia as a consequence of a 
number of comorbidities or a preexisting but asymptom-
atic gastrointestinal disease or an undetected infection – 
all of which could lead to intestinal inflammation and re-
lease of lactoferrin [30, 31]. Since by definition, these sub-
jects did not have a normal pregnancy, they were excluded 
from data analyses. Fecal lactoferrin levels appeared stable 
and below the threshold of normality in all the other sub-
jects during the 3 trimesters assessed as a group or sequen-
tially in individual subjects. In this study, we also con-
firmed that fecal lactoferrin is an accurate marker of IBD 
activity in this population of childbearing age. In 45 non-
pregnant patients with active IBDs within 18–40 years of 
age, we showed that the marker levels assessed at the time 
of colonoscopy closely correlated with the disease activity 
as determined by the endoscopic score in both UC and CD 
patients. The limitations of this study are the relatively 
small sample size and the lack of detailed characterization 
of the enrolled subjects who were considered to be healthy 
only on clinical grounds. Our data corroborate a number 
of other studies related to the use of fecal biomarkers in 
normal pregnancy and as a monitoring tool for IBDs [32, 
33].
A number of studies have focused on fecal marker lev-
els during normal pregnancy [34–36] and in pregnant 
women with IBDs. In the study by Barré et al. [34], the 
authors found that there were no differences in fecal lac-
toferrin levels between any trimester and prepregnancy 
levels (1.52 μg/g during pregnancy vs. 1.08 μg/g prepreg-
nancy [p = 0.08]) and, therefore, concluded that preg-
nancy has no effect on fecal lactoferrin levels. Likewise, 
there were no differences between prepregnancy and 
pregnancy levels in IBD patients. However, fecal lactofer-
rin was significantly higher in IBD patients compared to 
healthy pregnant controls at each trimester [34]. Similar 
results in a small group of patients have been published 
in abstract form by Koslowsky et al. [35] and, earlier, with 
fecal calprotectin by Julsgaard [36]. Bálint et al. [37] also 
did not find significant differences in fecal calprotectin 
concentrations between pregnant and nonpregnant 
healthy women.
Other studies have focused on the correlation of fecal 
biomarker levels with disease activity in IBDs as assessed 
by clinical activity indices. Rottenstreich et al. [38] stud-
ied in 157 pregnancies the correlation between fecal cal-
protectin levels in IBD patients during preconception, 
first trimester, second trimester, third trimester, and 
postpartum. Higher fecal calprotectin levels were found 
in all subjects who had active disease with fecal calprotec-
tin levels significantly correlated with physician global as-
sessment (PGA) and disease activity indices in all 5 peri-
ods. Furthermore, fecal calprotectin was noted to be sig-
nificantly higher in those patients who experienced a 
disease flare later in the gestation period compared to 
those who maintained clinical remission [38]. Barré et al. 
[34] found that during the third trimester, fecal lactofer-
rin levels significantly correlated with PGA, modified 
Harvey-Bradshaw Index (HBI) for CD, and partial Mayo 
Score for UC. Likewise, Huang et al. [39] reported that 
women with IBDs who had clinically active disease dur-
ing preconception and pregnancy had higher fecal cal-
protectin levels than women who had clinically inactive 
disease.
Kammerlander et al. [40] studied 219 pregnant wom-
en with moderate-severe IBDs (as assessed by HBI/pa-
tient-based Simple Clinical Colitis Activity Index or phy-
sician assessment) in treatment with anti-TNF agents and 
showed fecal calprotectin levels to be significantly higher 
in active compared to quiescent disease with a correlation 
of the biomarker level to disease activity in all gestational 
periods. They also found a fecal calprotectin sensitivity of 
69.7–80.0%, a specificity of 66.7–73.3%, and a positive 
predictive value of 66.7–74.4% over the 4 gestational pe-
riods (preconception and the 3 trimesters) when a cutoff 
of 200 mg/kg was used. They found no clinically signifi-
cant differences in CRP, albumin, or hemoglobin [40]. In 
another study, Julsgaard et al. [36] measured fecal calpro-
tectin levels in healthy pregnant women and compared 
them to those of pregnant women with active IBDs as as-
sessed by HBI/Simple Clinical Colitis Activity Index or 
PGA. Patients with active disease showed levels higher 
than controls, and the authors concluded that fecal cal-
protectin is a good indicator of IBD activity in pregnancy 
[36].
In another study, Kanis et al. [41] showed that fecal 
calprotectin shows an overall high sensitivity and speci-
ficity to identify disease activity. However, the usefulness 
of the biomarker to predict a clinical relapse at the subse-
quent trimester or postpartum was considered poor. In 
that study, the authors considered fecal calprotectin val-





lish the individual threshold value above which a clinical 
flare can be expected. Such value might considerably dif-
fer among patients based upon their baseline disease bur-
den.
It has been rightly pointed out that there is a lack of 
studies comparing the accuracy of stool markers against 
the IBD gold-standard method (endoscopy) for assessing 
disease activity during pregnancy [32, 33]. Clinical scores, 
which have been used to assess the markers’ accuracy, 
mostly reflect subjective symptoms which are difficult to 
assess during pregnancy. Regardless, both fecal lactofer-
rin and calprotectin appear superior to any other nonin-
vasive marker (such as CRP, hemoglobin, and albumin) 
to monitor IBDs during pregnancy [32].
In conclusion, our study supports other observations 
and shows that fecal lactoferrin levels during normal 
pregnancy are superimposable to those of nonpregnant 
women and significantly below levels of nonpregnant 
women of the same childbearing age with active IBDs. 
Current data indicate that stool marker levels (both lac-
toferrin and calprotectin) correlate to disease activity 
during pregnancy. Hence, they can be potentially used to 
monitor disease activity in pregnant IBD patients.
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